Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Policy / Pricing

FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results

 April 13, 2026

FDA

The U.S.

Policy / PricingRead full story

Post navigation

USP adds Tamiflu, Trulicity to vulnerable list as upstream analysis reshapes supply concerns →
← Allogene data suggest ‘off-the-shelf’ CAR-T could delay relapse in lymphoma

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com